Regulatory Filings • Mar 5, 2025
Regulatory Filings
Open in ViewerOpens in native device viewer
Circio presents results that further validate the circVec circular RNA platform at two international industry conferences
Oslo, Norway 5 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, today announces that CEO Dr. Erik Digman Wiklund and CSO Dr.
Victor Levitsky are presenting updated data demonstrating the significant
advantages of Circio's circular RNA circVec platform compared to current mRNA
-based vector technology. The data further strengthens the in vitro and in vivo
validation of Circio's platform. The presentations are being delivered at two
major biopharma industry conferences in Basel, Switzerland, and Stockholm,
Sweden.
The presentations detail the advantages and potential of the circVec 3.0
generation to improve on current mRNA-based technology for a range of
therapeutic applications. In vivo expression data has shown an estimated circRNA
half-life of over 600 hours vs. under 10 hours for linear mRNA, which translates
to over 70 times prolonged RNA durability and 15 times enhanced protein
expression.
Novel systemic LNP-delivery data demonstrates robust and durable circVec
expression in spleen, far outperforming equivalent mRNA-vectors. This important
finding has the potential to open up attractive therapeutic opportunities for
the circVec technology in several areas, such as cell therapy. Further
experimental work is currently ongoing to validate and characterize these
observations.
"The recent results showing efficient and specific circVec delivery to spleen
are very promising and hints at novel opportunities for our circular RNA
platform in cell and immune therapies," said Dr. Victor Levitsky, CSO of
Circio. "A broad set of experiments to further investigate this observation, as
well as in vivo testing of the novel circVec 3.0 generation, will read out over
the next 6-12 weeks. The performance of circVec 3.0-AAV constructs is of
particular interest, which we believe has the potential to transform current
gold-standard AAV gene therapy and generate substantial partnering interest."
See below for titles and presentation materials:
RNA Leaders Europe Congress (https://informaconnect.com/rna-leaders
-europe/agenda/2/)
Title: Deploying circular RNA expression to boost gene therapy - AAV and beyond
Time & place: 5 March 2025, Basel, SwitzerlandPresenter: Dr. Erik Digman
Wiklund, CEO
Biologics World Nordics 2025 (https://www.imapac.com/events/biologics-world
-nordics-2025)
Title: CircVec - A Novel Payload Expression Platform Based on Circular RNA
Biogenesis: Features and Opportunities
Time & place: 5 March 2025, Stockholm, Sweden
Presenter: Dr. Victor Levitsky, CSO
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: [email protected]
Neil Hunter - Hunter PR
Phone:+44 7821 255568 (http://tel:+447821255568)
Email: [email protected]
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.